The FDA has approved the subcutaneous administration of a fixed combination of amivantamab (Rybrevant; Johnson & Johnson) and a recombinant human hyaluronidase for patients with non–small cell lung ...
The FDA approves a new subcutaneous formulation of amivantamab, enhancing treatment for advanced lung cancer with reduced administration time and improved safety.
Introduction Refractory headache is a common and frequently disabling disorder, affecting 2–12 million patients each year in ...
The U.S. Food and Drug Administration (FDA) have granted approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), ...
The final, formatted version of the article will be published soon. Background: Intravenous infusion is a key part of nursing practice, and its scientific reliability and safety directly affect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback